.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Accenture
Healthtrust
Cerilliant
Citi
Harvard Business School
Teva
Dow
McKinsey

Generated: July 20, 2017

DrugPatentWatch Database Preview

OPTIVAR Drug Profile

« Back to Dashboard

What is the patent landscape for Optivar, and when can generic versions of Optivar launch?

Optivar is a drug marketed by Mylan Speciality Lp and is included in one NDA.

The generic ingredient in OPTIVAR is azelastine hydrochloride. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride profile page.

Summary for Tradename: OPTIVAR

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list80
Patent Applications: see list3,608
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OPTIVAR at DailyMed

Pharmacology for Tradename: OPTIVAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp
OPTIVAR
azelastine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021127-001May 22, 2000ATRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OPTIVAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp
OPTIVAR
azelastine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021127-001May 22, 20005,164,194► Subscribe
Mylan Speciality Lp
OPTIVAR
azelastine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021127-001May 22, 20005,164,194*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: OPTIVAR

Drugname Dosage Strength RLD Submissiondate
azelastine hydrochlorideOphthalmic Solution0.05%Optivar12/13/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
McKesson
Mallinckrodt
Merck
Express Scripts
US Department of Justice
AstraZeneca
Julphar
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot